Systematic Literature Review of Unmet Needs and Burden of Disease in Generalized Anxiety Disorder (GAD)
Author(s)
Erin Ferries1, Susan Suponcic, BA, MA, MSc, PhD2, sophia chung, BS3, Sayak Bhattacharya, BA3, Aishwarya Kulkarni, MS3, Mason Yeh, PhD3, Abigail Silber, MPH3, Matt O'Hara, MBA3, Rafael Muniz, MD4, Tirso Alonso, MD, MBA, MHA4, Phong Duong, BSc, PharmD4;
1MindMed, HEOR, Denver, CO, USA, 2Value and Access Advisors, LLC, St. Petersburg, FL, USA, 3Trinity Life Science, Princeton, NJ, USA, 4MindMed, New York, NY, USA
1MindMed, HEOR, Denver, CO, USA, 2Value and Access Advisors, LLC, St. Petersburg, FL, USA, 3Trinity Life Science, Princeton, NJ, USA, 4MindMed, New York, NY, USA
Presentation Documents
OBJECTIVES: The prevailing consensus suggests patients with General Anxiety Disorder (GAD) experience substantial burden of illness and impact on quality of life (QoL). However, gaps remain in understanding the full impact of GAD. We aim to conduct a systematic literature review (SLR) to assess GAD's clinical, humanistic, and economic burden.
METHODS: An ongoing SLR using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist will identify peer-reviewed manuscripts and conference abstracts published in English from November 2004 to December 2024 in PubMed, MEDLINE, and Embase. An Artificial Intelligence (AI)-enhanced platform facilitates the review process. The validated AI screening platform was trained on the first 50 title/abstract screenings and further validated during ongoing screening. Title and abstract screening with one person and one pass of the AI screener provide reviewer-level decisions with adjudication by another independent person. Full-text screening will be conducted by three separate human reviewers.
RESULTS: A total of 27,173 articles were identified in PubMed (N=13,989) and Embase (N=18,807). Deduplication of records in EndNote resulted in 18,759 articles. Full-text screening is ongoing and has identified a wide evidence base supporting the burden of GAD. The count of papers (non-mutually exclusive) identified by key topics of interest include, but are not limited to: GAD clinical trials (N=516); observational studies (N=202); epidemiological studies (N=101); QoL studies (N=553); patient-reported outcomes (PROs) (N=221); economic impact (N=37); comorbidities (N=732); treatment response (N=177) and impact on functioning / activities of daily livings (N=44). The full complement of data will be available for presentation in May 2025.
CONCLUSIONS: To the authors’ knowledge, this is the first SLR, spanning 20 years of published literature, to elucidate and enumerate gaps in epidemiology, diagnosis criteria, burden of disease, treatment outcomes, and unmet needs that are specific to GAD.
METHODS: An ongoing SLR using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist will identify peer-reviewed manuscripts and conference abstracts published in English from November 2004 to December 2024 in PubMed, MEDLINE, and Embase. An Artificial Intelligence (AI)-enhanced platform facilitates the review process. The validated AI screening platform was trained on the first 50 title/abstract screenings and further validated during ongoing screening. Title and abstract screening with one person and one pass of the AI screener provide reviewer-level decisions with adjudication by another independent person. Full-text screening will be conducted by three separate human reviewers.
RESULTS: A total of 27,173 articles were identified in PubMed (N=13,989) and Embase (N=18,807). Deduplication of records in EndNote resulted in 18,759 articles. Full-text screening is ongoing and has identified a wide evidence base supporting the burden of GAD. The count of papers (non-mutually exclusive) identified by key topics of interest include, but are not limited to: GAD clinical trials (N=516); observational studies (N=202); epidemiological studies (N=101); QoL studies (N=553); patient-reported outcomes (PROs) (N=221); economic impact (N=37); comorbidities (N=732); treatment response (N=177) and impact on functioning / activities of daily livings (N=44). The full complement of data will be available for presentation in May 2025.
CONCLUSIONS: To the authors’ knowledge, this is the first SLR, spanning 20 years of published literature, to elucidate and enumerate gaps in epidemiology, diagnosis criteria, burden of disease, treatment outcomes, and unmet needs that are specific to GAD.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
SA5
Topic
Study Approaches
Topic Subcategory
Literature Review & Synthesis
Disease
SDC: Mental Health (including addition)